Latest Factsheet
Next Generation Ion Mobility Mass Spectrometry-based Proteomics Services
Next Generation Ion Mobility Mass Spectrometry-based Proteomics Services
by Linda Xue, PhD, Principal Scientist, Crown Bioscience
Crown Bioscience is a Contract Research Organization (CRO) driven by our mission is to empower our customers to improve human health.
We do this by engaging the finest scientific talent, upholding the highest quality standards, and relentlessly pursuing innovation.
Every day we strive to accelerate and de-risk drug development to help realize a world where every patient gets the right treatment, at the right time.
Crown Bioscience to Acquire Indivumed’s Service Business and Supporting Biobank
Leverage our extensive experience in oncology, immuno-oncology, immune-mediated inflammatory and cystopathic diseases
Discover the largest commercially available collection of PDX models as well as our novelin vitro models
Utilize our bioinformatics, biomarker analysis, genomics and high content imaging services to advance your preclinical studies
Accelerate your drug development with our biomarker discovery, efficacy testing, DMPK and pharmacology services
Latest Factsheet
Next Generation Ion Mobility Mass Spectrometry-based Proteomics Services
Latest Application Note
Evaluate immunotherapeutics and agents to overcome drug resistance with our NSCLC EGFR exon 19 deletion resources
Latest Poster
3D Ex vivo Patient Tissue Platform for Immuno-Oncology Drug Testing
Latest Webinar
Preclinical biomarker discovery via in vivo and in vitro screening
January 11, 2023
It is well-known that drug attrition rates for anticancer agents are very high. In fact, only about 5% of compounds in preclinical development eventually becoming approved for clinical use. The need for more clinically relevant preclinical models has been identified as one of the areas that can reduce this attrition rate by enabling better decisions when selecting agents to advance to the clinic.
December 15, 2022
3D adult stem cell (ASC)-derived tumor organoids can enhance the translatability of drug discovery data, especially in combination with high content imaging (HCI). In this blog post, we explore how the pairing of these two technologies allows researchers to develop highly comprehensive and predictive data that can enable better decisions earlier in drug discovery, while improving the translatability of the most promising lead compounds.
November 30, 2022
This post explores applications of genetically engineered organoids and cell lines to expand and accelerate anti-cancer drug discovery and development. We first provide a brief overview of two major methods that are used to develop engineered organoids/cell lines (i.e., lentiviral transduction and PiggyBac), followed by typical workflows for generating these models. Several case studies are presented to showcase their application for target validation and in vitro /in vivo efficacy studies.
November 10, 2022
Drug development is a lengthy, risky, and costly endeavor with high candidate attrition. Attrition rates for anticancer agents are much higher than in other therapeutic categories. Only 5% of them are estimated to reach the clinical stage. This very high rate has been attributed in part to the poor translatability of current preclinical data.
© 2023 Crown Bioscience. All Rights Reserved. Privacy Policy
© 2023 Crown Bioscience. All Rights Reserved. Privacy Policy